TVTX: SEC Form 10-K filed by Travere Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for TVTX
Across the 12 sessions after earlier TVTX headlines, the stock closed higher 4 times and lower 8 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TVTX | SPY |
|---|---|---|---|
| Feb 20, 2026 | Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | +3.7% | +0.7% |
| Feb 13, 2026 | Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results | -9.1% | +0.1% |
| Feb 12, 2026 | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +1.3% | -1.5% |
| Feb 5, 2026 | Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit | -7.0% | -1.2% |
| Jan 13, 2026 | Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGSand 1 other headline that session | -14.6% | -0.2% |
| Jan 6, 2026 | Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | -6.1% | +0.6% |
Quantisnow market dataNASDAQ
TVTX
Travere Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TVTX
Full TVTX profile on Quantisnow Follow TVTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time